Chairman of the Board. Adjunct Professor of Cancer Biology, whose research focuses on rare cancers.
Professor of Oncology and the European key opinion leader of GIST therapies.
Ph.D. student, whose research focus is on new therapeutic targets in GIST.
An innovative Professor of Molecular Precision Medicine.
CEO of Herantis Pharma.
Upcoming events and news
Read more about the program (Finnish). https://www.sttinfo.fi/tiedote/future-health-and-wellbeing-kasvupolulle-ratkaisuja-jotka-voivat-mullistaa-maailmaa?publisherId=26883916&releaseId=69857410
Meet us at the Anglonordic Life Science Conference in London. http://anglonordic.biopartnering.co.uk/
Sartar was awarded a Japan patent for use of anagrelide in cancer therapy.
Sartar strengthens the board of directors. CEO of Herantis Pharma, Pekka Simula, has been appointed as a new member to the Sartar Therapeutics board of directors.